A detailed history of Tower Research Capital LLC (Trc) transactions in Arvinas, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 8,564 shares of ARVN stock, worth $160,403. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,564
Previous 5,713 49.9%
Holding current value
$160,403
Previous $152,000 38.16%
% of portfolio
0.01%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $67,454 - $93,313
2,851 Added 49.9%
8,564 $210,000
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $118,533 - $195,778
4,846 Added 558.94%
5,713 $152,000
Q1 2024

May 15, 2024

SELL
$36.38 - $52.31 $213,114 - $306,431
-5,858 Reduced 87.11%
867 $35,000
Q4 2023

Feb 13, 2024

BUY
$14.19 - $42.33 $46,358 - $138,292
3,267 Added 94.48%
6,725 $276,000
Q3 2023

Nov 14, 2023

SELL
$19.64 - $28.21 $118,291 - $169,908
-6,023 Reduced 63.53%
3,458 $67,000
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $90,722 - $131,220
4,175 Added 78.68%
9,481 $235,000
Q1 2023

May 09, 2023

BUY
$26.15 - $37.26 $50,626 - $72,135
1,936 Added 57.45%
5,306 $145,000
Q4 2022

Feb 10, 2023

SELL
$32.47 - $57.24 $89,844 - $158,383
-2,767 Reduced 45.09%
3,370 $115,000
Q3 2022

Nov 10, 2022

BUY
$41.87 - $57.99 $141,394 - $195,832
3,377 Added 122.36%
6,137 $273,000
Q2 2022

Aug 15, 2022

BUY
$36.01 - $74.24 $84,011 - $173,201
2,333 Added 546.37%
2,760 $117,000
Q1 2022

May 12, 2022

SELL
$60.27 - $81.57 $11,632 - $15,743
-193 Reduced 31.13%
427 $29,000
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $81,456 - $119,011
-1,237 Reduced 66.61%
620 $51,000
Q3 2021

Nov 15, 2021

SELL
$73.2 - $107.87 $77,884 - $114,773
-1,064 Reduced 36.43%
1,857 $153,000
Q2 2021

Aug 16, 2021

SELL
$60.45 - $84.26 $207,948 - $289,854
-3,440 Reduced 54.08%
2,921 $225,000
Q1 2021

May 17, 2021

BUY
$58.19 - $91.37 $300,493 - $471,834
5,164 Added 431.41%
6,361 $421,000
Q4 2020

Feb 16, 2021

SELL
$20.19 - $84.93 $305,696 - $1.29 Million
-15,141 Reduced 92.67%
1,197 $102,000
Q3 2020

Nov 16, 2020

BUY
$22.99 - $36.34 $310,479 - $490,771
13,505 Added 476.7%
16,338 $386,000
Q2 2020

Aug 13, 2020

BUY
$29.88 - $56.74 $84,650 - $160,744
2,833 New
2,833 $95,000
Q1 2020

May 15, 2020

SELL
$33.0 - $54.5 $7,359 - $12,153
-223 Closed
0 $0
Q4 2019

Feb 07, 2020

SELL
$15.39 - $44.38 $30,333 - $87,472
-1,971 Reduced 89.84%
223 $9,000
Q3 2019

Nov 05, 2019

BUY
$21.55 - $27.61 $47,280 - $60,576
2,194 New
2,194 $47,000
Q2 2019

Aug 13, 2019

SELL
$15.96 - $23.8 $4,963 - $7,401
-311 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$13.55 - $23.79 $7,750 - $13,607
-572 Reduced 64.78%
311 $5,000
Q4 2018

Feb 14, 2019

BUY
$11.19 - $18.56 $9,880 - $16,388
883 New
883 $11,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.